Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946283 · ClinicalTrials.gov registry record · NA
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00946283 is a NA study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 30 participants.
The verdict
NCT00946283, a NA study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Probiotics, such as Lactobacillus, may be effective in preventing infections in patients with suppressed immune systems. PURPOSE: This phase I trial is studying the side effects and how well giving enteral nutrition, including Lactobacillus, works in preventing infections in patients undergoing donor stem cell transplant for hematologic cancer or myelodysplastic syndrome.
Interventions
- DIETARY_SUPPLEMENT Lactobacillus rhamnosus GG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-10-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946283
The ClinicalTrials.gov registry entry for NCT00946283 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lactobacillus rhamnosus GG is the first listed.
NCT00946283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946283 about?
NCT00946283 is a clinical study titled "Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome". RATIONALE: Probiotics, such as Lactobacillus, may be effective in preventing infections in patients with suppressed immune systems. PURPOSE: This phase I trial is studying the side effects and how well giving enteral nutrition, including Lactobacillus, works in preventing infections in patients und...
What is the current status of trial NCT00946283?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2010-03. Estimated completion is 2015-10-14.
What interventions are being tested in trial NCT00946283?
The interventions under investigation include: Lactobacillus rhamnosus GG (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00946283?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.